Carboxamides (i.e., R-c(=o)-n, Wherein R Is A Radical Having Carbon Bonded Directly To The C(=o)-n Or Is Hydrogen And Wherein Any Substituent Attached To Nitrogen Will Be Referred To As E) Patents (Class 514/613)
  • Patent number: 10287288
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 14, 2019
    Assignee: Bristol-Myers Squibb
    Inventors: Kumar Balashanmuga Pabbisetty, James R. Corte, Andrew K. Dilger, William R. Ewing, Yeheng Zhu
  • Patent number: 10130585
    Abstract: Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are provided.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: November 20, 2018
    Assignee: Murray and Poole Enterprises Limited
    Inventor: Susanne Riel
  • Patent number: 10105319
    Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: October 23, 2018
    Assignee: Murray and Poole Enterprises Limited
    Inventor: Susanne Riel
  • Patent number: 9909178
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 6, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Patent number: 9890118
    Abstract: Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 13, 2018
    Assignee: ALLERGAN, INC.
    Inventors: David F. Woodward, Robert M. Burk
  • Patent number: 9635853
    Abstract: The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests wherein R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts thereof.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: May 2, 2017
    Assignee: Syngenta Participations AG
    Inventors: Ottmar Franz Hueter, Thomas Pitterna, Andre Stoller, Andrew Edmunds, Pierre Joseph Marcel Jung
  • Patent number: 9622968
    Abstract: A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure and correct hypovolemia.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: April 18, 2017
    Assignee: VIVACELLE BIO, INC.
    Inventor: Cuthbert O. Simpkins
  • Patent number: 9422352
    Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: August 23, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Xiao-Jing Wang, Qinghong Zhang, Yosef Refaeli
  • Patent number: 9387162
    Abstract: A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: July 12, 2016
    Assignee: VIVACELLE BIO, INC.
    Inventor: Cuthbert O. Simpkins
  • Patent number: 9340488
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 17, 2016
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavy
  • Patent number: 9095609
    Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 4, 2015
    Assignees: UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (C.S.I.C.)
    Inventors: Carlos Belmonte Martnez, Juana Gallar Martinez, Antonio Ferrer Montiel, Asia Fernández Carvajal, Félix Viana De La Iglesia
  • Patent number: 9050294
    Abstract: Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, prodrugs, precursors thereof, and/or salts thereof, are described.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: June 9, 2015
    Assignee: Royal Institution for the Advancement of Learning/McGill University
    Inventors: Danuta Radzioch, Samuel David, Ruben Lopez-Vales, Thomas Skinner
  • Publication number: 20150139915
    Abstract: Methods and compositions are described for reducing airway reactivity and the susceptibility to asthmatic bronchoconstriction that involve increasing sphingolipid content in airways and lungs of a mammalian subject.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Stefan Worgall, Tilla S. Worgall
  • Publication number: 20150133546
    Abstract: The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided.
    Type: Application
    Filed: January 17, 2015
    Publication date: May 14, 2015
    Inventors: Zuhal Butuner, Deepank Utkhede, Sylie Sim, David J. Wiseman
  • Publication number: 20150133540
    Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, satur
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Inventor: Robert H. Bedoukian
  • Publication number: 20150126437
    Abstract: The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules.
    Type: Application
    Filed: October 17, 2012
    Publication date: May 7, 2015
    Applicant: The Regents of the University of California
    Inventors: Anandasankar Ray, Sean Michael Boyle
  • Publication number: 20150111969
    Abstract: Provided is a compound of formula (I): a pharmaceutical composition comprising the compound of formula (I), a pharmaceutical composition comprising anandamide (AEA) and methods of using the same in the treatment of non-melanoma skin cancer (NMSC) and colorectal cancer.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Rukiyah T. Van Dross, Daniel A. Ladin, Colin S. Burns, Allison Stokes Danell
  • Patent number: 8993631
    Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventor: Shi Yin Foo
  • Patent number: 8993632
    Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: March 31, 2015
    Assignee: AbbVie Inc.
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jeffrey J. Rohde, Qi Shuai, James T. Link, Jyoti R. Patel, Jurgen Dinges, Bryan K. Sorensen, Hong Yong, Vince S. Yeh, Ravi Kurukulasuriya
  • Publication number: 20150051276
    Abstract: Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils.
    Type: Application
    Filed: April 30, 2013
    Publication date: February 19, 2015
    Inventor: Robert H. Bedoukian
  • Patent number: 8946262
    Abstract: Methods of preventing and treating gastrointestinal dysfunction, particularly postoperative ileus and post-partum ileus, in a patient undergoing surgery or other biological stress by administering 4-aryl-piperidine derivatives are disclosed.
    Type: Grant
    Filed: November 29, 2004
    Date of Patent: February 3, 2015
    Assignee: Adolor Corporation
    Inventors: David D Christ, Bruce A Wallin, Deanne D Garver, William K Schmidt, David Jackson
  • Patent number: 8945603
    Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: February 3, 2015
    Assignee: Boston Foundation for Sight
    Inventor: Perry Rosenthal
  • Patent number: 8933127
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: January 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Patent number: 8933122
    Abstract: Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the treatment of objects which are infected with spores. The spores may originate from bacteria or fungi.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: January 13, 2015
    Assignee: Laboratorios Miret, S.A.
    Inventors: Xavier Rocabayera Bonvila, Sergi Figueras Roca, Roger Segret Pons, Eva Piera Eroles
  • Patent number: 8927608
    Abstract: A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier
  • Patent number: 8916613
    Abstract: The invention relates to insecticide mixtures comprising thiodicarb and at least one other known active ingredient from the category of chloronicotinyls, as well as the use of these mixtures to control animal pests.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: December 23, 2014
    Assignee: Bayer CropScience AG
    Inventors: Wolfram Andersch, Heike Hungenberg, Wolfgang Thielert
  • Patent number: 8895620
    Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more 1-(2,6-dichloro-?,?,?-trifluoroparatolyl)pyrazole compound(s) selected from Group (A) shows an excellent controlling activity on a pest. Group (A): a group consisting of acetoprole, ethiprole, fipronil, vaniliprole, pyriprole and pyrafluprole.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: November 25, 2014
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: So Kiguchi, Soichi Tanaka
  • Patent number: 8889906
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: November 18, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Robert Greenhouse, Ralph New Harris, III, Saul Jaime-Figueroa, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Patent number: 8877809
    Abstract: Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C20-retinoid in an amount sufficient to reduce accumulation of a lipofuscin pigment in the retina. Further provided are methods of retarding formation of A2E and/or ATR-dimer by replacing an all-frans-retinal (ATR) substrate with a C20-D3-retinal substrate under conditions sufficient to impede the formation of A2E. Compositions for retarding formation of a lipofuscin pigment in the retina containing a substituted C20-retinoid and a pharmaceutically acceptable carrier are also provided.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: November 4, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Ilyas Washington
  • Publication number: 20140323561
    Abstract: Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I).
    Type: Application
    Filed: October 21, 2013
    Publication date: October 30, 2014
    Inventor: Robert H. Bedoukian
  • Publication number: 20140302102
    Abstract: The present invention discloses a cosmetic for the lips comprising spherical micro particles of silica, emollients and gel, as well as cosmetically acceptable excipients. The present invention also refers to the fabrication process of the said cosmetic and the use thereof.
    Type: Application
    Filed: August 31, 2011
    Publication date: October 9, 2014
    Applicant: NATURA COSMÉTICOS S.A.
    Inventors: Ana Paula Nagamatsu, Joyce Kazue Alves Wada, Marcos Rogerio Spina
  • Patent number: 8853281
    Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: October 7, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Anna Karin Belfrage, Bjorn Classon, Urszula Grabowska, Ellen Hewitt, Vladimir Ivanov, Daniel Jönsson, Pia Kahnberg, Peter Lind, Magnus Nilsson, Lourdes Odén, Mikael Pelcman, Horst Wähling
  • Patent number: 8853452
    Abstract: Compounds and their syntheses are disclosed herein. Compositions and pharmaceutical compositions comprising a compound are also described, and include compositions also comprising liposomes. Methods for the treatment of cancer in animals comprising administering a compound or a composition comprising a compound are also described.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: October 7, 2014
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Barbara S. Beckman, Maryam Foroozesh, Jiawang Liu
  • Publication number: 20140296294
    Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Xiang-qun XIE, Peng YANG, Rentian FENG
  • Publication number: 20140288184
    Abstract: The present invention provides a glyoxime derivative displaying excellent pesticidal effect or a salt thereof and a pesticide containing the same as an active ingredient. This pesticide is characterized by containing as an active ingredient, a glyoxime derivative expressed by the general formula [I] (in which X represents a cyano group or a carbamoyl group, R1 represents a C1˜C8 alkyl group, a C3˜C6 cycloalkyl C1˜C6 alkyl group, etc, and IV represents a hydrogen atom, a C1˜C8 alkyl group, a C3˜C6 cycloalkyl C1˜C6 alkyl group, etc.) or an agriculturally acceptable salt thereof.
    Type: Application
    Filed: November 19, 2012
    Publication date: September 25, 2014
    Applicants: IHARA CHEMICAL INDUSTRY CO., LTD., KUMIAI CHEMICAL INDUSTRY CO., LTD.
    Inventors: Shunichirou Fukumoto, Daisuke Shikama, Toshihiro Nagata, Katsuya Kato, Kei Kawamoto, Masaaki Komatsu, Takeshi Matsuda, Seisuke Ito
  • Patent number: 8840923
    Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 23, 2014
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
  • Publication number: 20140249160
    Abstract: Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.
    Type: Application
    Filed: February 6, 2014
    Publication date: September 4, 2014
    Applicant: Edison Pharmaceuticals, Inc.
    Inventor: Guy M. MILLER
  • Publication number: 20140243414
    Abstract: The invention provides pharmaceutical compositions comprising a cholesteryl ester transfer protein (CETP) inhibitor and a water-insoluble concentration-enhancing additive, which exhibit improved bioavailability. The invention also provides methods of treating cardiovascular disorders comprising the administration of the pharmaceutical compositions comprising a CETP inhibitor.
    Type: Application
    Filed: July 26, 2013
    Publication date: August 28, 2014
    Applicant: Japan Tobacco Inc.
    Inventor: Yoshifumi Uemoto
  • Patent number: 8809395
    Abstract: The present invention is directed to compounds, intermediates and methods for making valerenic acid and its derivatives as well as the use of such compounds as GABAA receptor ligands.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 19, 2014
    Assignee: Valericon GmbH
    Inventors: Johann Mulzer, Jürgen Ramharter, Steffen Hering, Sophia Khom
  • Publication number: 20140228443
    Abstract: Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 14, 2014
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Feng Hong, Ryo Kubota, Jennifer Gage
  • Publication number: 20140228405
    Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like.
    Type: Application
    Filed: August 8, 2012
    Publication date: August 14, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Naoki Tomita, Shigeo Kajii, Douglas Robert Cary, Daisuke Tomita, Shinichi Imamura, Ken Tsuchida, Satoru Matsuda, Ryujiro Hara
  • Patent number: 8784873
    Abstract: The invention provides a method of changing a ratio of 68 to 64 kDa protein of MRJP3 in a royal jelly, a method of producing a royal jelly comprising MRJP3 having a changed ratio of 68 to 64 kDa protein relative to a control royal jelly and the royal jelly produced thereform. Also provided is a method of promoting the growth of the larva of a queen bee comprising feeding the larva of the queen bee a royal jelly of the invention. Further provided is a method of producing bee larva, pupa and queen bees with sizes larger than normal.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: July 22, 2014
    Assignee: Naturewise Biotech & Medicals Corporation
    Inventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jung Chen, Wei-Jan Huang, Li-Ling Chi
  • Patent number: 8778923
    Abstract: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: July 15, 2014
    Assignee: Receptos, Inc.
    Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Junko Tamiya, Liming Huang, Adam R. Yeager, Enugurthi Brahmachary, Thomas Fowler, Andrew Novak, Premji Meghani, Michael Knaggs
  • Patent number: 8778997
    Abstract: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: July 15, 2014
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Yarlagadda Sudhakara Babu, Pooran Chand, Shanta Bantia, Shane Arnold, John Michael Kilpatrick
  • Patent number: 8778838
    Abstract: The present invention relates to aqueous concentrate formulations for plant protection comprising: 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide in the form of its anhydrate; N-(phosphonomethyl)glycine in the form of its free acid, in the form of the ammonium salt or a substituted ammonium salt or a mixture thereof; at least two different non-ionic surfactants with at least one of them comprising an ethylene oxide polymer moiety or an ethylene oxide/C3-C4-alkylene oxide block copolymer moiety, and water; wherein the pH-value of the formulation is below 6.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: July 15, 2014
    Assignee: BASF SE
    Inventors: Michael Krapp, Wolfgang Gregori, Sven Adam, Klaus Kolb, Juergen Jakob, Bernd Sievernich, Joerg Steuerwald, Steven Bowe, Joseph Zawierucha, Rex Liebl
  • Patent number: 8765815
    Abstract: Compounds that can be used as openers or blockers of voltage-dependent potassium channels, and which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing or enhancing cortical and/or peripheral neuron activity, compositions containing same and methods utilizing same are disclosed. Also disclosed are modulators of voltage-dependent potassium channels, which exhibit blocking of a TRPV1 channel, and hence are useful in the treatment of TRPV1-related conditions.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: July 1, 2014
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Bernard Attali, Asher Peretz
  • Patent number: 8759401
    Abstract: Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: June 24, 2014
    Assignee: Akorn, Inc.
    Inventors: Abu Alam, Elias Reichel, Brandon Busbee
  • Patent number: 8759400
    Abstract: The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, this invention relates to compositions and methods for selectively enhancing fungal sensitivity to antifungal compounds.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: June 24, 2014
    Assignee: MethylGene Inc.
    Inventors: Nafsika Georgopapadakou, Wenqi Hu, Nadia Campeol, Jean Bedard, Robert Deziel, Alain Ajamian
  • Patent number: 8754041
    Abstract: The method of removing Escherichia coli (E. coli) bacteria from an aqueous solution includes the step of mixing multi-walled carbon nanotubes functionalized with a dodecylamine group (C12H27N) into an aqueous solution containing E. coli bacteria. The multi-walled carbon nanotubes functionalized with a dodecylamine group have an antimicrobial effect against the E. coli bacteria. The multi-walled carbon nanotubes may be mixed into the aqueous solution at a concentration of between approximately 0.2 g and 0.007 g of multi-walled carbon nanotubes functionalized with a dodecylamine group per 100 ml of the aqueous solution.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: June 17, 2014
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Muataz Ali Atieh, Amjad Bajes Khalil, Tahar Laoui, Samer Mohammed Al-Hakami
  • Patent number: 8748661
    Abstract: The present invention relates to novel polyamino polyketide antibiotics, methods of their production as well as methods of using these antibiotics, for example, for inhibition or removal of biofilm formation or for treating bacterial infection with these antibiotics.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: June 10, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Jien Wu, Haibao Zhang, Lianhui Zhang